New User:

-or-
Username:
Password:
Forgot your password?

Stock Market & Financial Investment News

News Breaks
August 15, 2014
07:55 EDTVTLVital Therapies price target raised to $35 from $20 at Canaccord
Canaccord raised its price target on Vital Therapies to $35 from $20 based on the probability of the success of its Alcohol Induced Liver Disease drug and its substantial market opportunity. Canaccord maintains its Buy rating on Vital Therapies.
News For VTL From The Last 14 Days
Sign up for a free trial to see the rest of the stories you've been missing.
There are no results for VTL

Sign up for a free trial to see the rest of the stories you've been missing.

I agree to the theflyonthewall.com disclaimer & terms of use